Literature DB >> 32213074

Evolving therapeutic goals in Crohn's disease management.

Thomas Chateau1,2, Laurent Peyrin-Biroulet2.   

Abstract

The main objectives in Crohn's disease are to avoid disease complications and preserve the patient's quality of life. Early disease control and close monitoring with specific targets to reach might be the only way to change the disease course. In two decades, we have moved from clinical response to full remission (clinical and endoscopic remission) requiring a tight monitoring of both symptoms and objective signs of inflammation. This review summarizes the concepts of tight control and treat-to-target and their potential for disease modification.

Entities:  

Keywords:  Crohn's disease; Tight control; treat-to-target

Mesh：

Substances：

Year:  2019        PMID： 32213074      PMCID： PMC7079266          DOI： 10.1177/2050640619887316

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN： 2050-6406            Impact factor:   4.623


  60 in total

1.  Early rheumatoid arthritis.

Authors:  Adam Young; Tom Huizinga
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-02       Impact factor: 4.098

2.  Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.

Authors:  Ingrid Ordás; Jordi Rimola; Sonia Rodríguez; José M Paredes; María J Martínez-Pérez; Esther Blanc; Juan A Arévalo; Marta Aduna; Montserrat Andreu; Alexander Radosevic; Anna M Ramírez-Morros; Susana Pinó; Marta Gallego; Aranzazu Jauregui-Amezaga; Elena Ricart; Julián Panés
Journal:  Gastroenterology       Date:  2013-10-29       Impact factor: 22.682

3.  ECCO-ESCP Consensus on Surgery for Crohn's Disease.

Authors:  Willem A Bemelman; Janindra Warusavitarne; Gianluca M Sampietro; Zuzana Serclova; Oded Zmora; Gaetano Luglio; Anthony de Buck van Overstraeten; John P Burke; Christianne J Buskens; Francesco Colombo; Jorge Amil Dias; Rami Eliakim; Tomás Elosua; I Ethem Gecim; Sanja Kolacek; Jaroslaw Kierkus; Kaija-Leena Kolho; Jérémie H Lefevre; Monica Millan; Yves Panis; Thomas Pinkney; Richard K Russell; Chaya Shwaartz; Carolynne Vaizey; Nuha Yassin; André D'Hoore
Journal:  J Crohns Colitis       Date:  2018-01-05       Impact factor: 9.071

4.  Impact of disease location on fecal calprotectin levels in Crohn's disease.

Authors:  Krisztina B Gecse; Johannan F Brandse; Sandra van Wilpe; Mark Löwenberg; Cyriel Ponsioen; Gijs van den Brink; Geert D'Haens
Journal:  Scand J Gastroenterol       Date:  2015-01-30       Impact factor: 2.423

5.  The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials.

Authors:  Laurent Peyrin-Biroulet; Corinne Gower-Rousseau
Journal:  J Crohns Colitis       Date:  2016-09-23       Impact factor: 9.071

6.  Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study).

Authors:  Inger C Solberg; Milada Cvancarova; Morten H Vatn; Bjørn Moum
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

Review 7.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

8.  Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease.

Authors:  Marie-Lise Thierry; Hélène Rousseau; Lieven Pouillon; Mélanie Girard-Gavanier; Cédric Baumann; Anthony Lopez; Silvio Danese; Valérie Laurent; Laurent Peyrin-Biroulet
Journal:  J Crohns Colitis       Date:  2018-11-09       Impact factor: 9.071

9.  Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.

Authors:  Laurent Peyrin-Biroulet; Alarcos Cieza; William J Sandborn; Michaela Coenen; Yehuda Chowers; Toshifumi Hibi; Nenad Kostanjsek; Gerold Stucki; Jean-Frédéric Colombel
Journal:  Gut       Date:  2011-06-05       Impact factor: 23.059

10.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Authors:  David M Faleck; Adam Winters; Shreya Chablaney; Preeti Shashi; Joseph Meserve; Aaron Weiss; Satimai Aniwan; Jenna L Koliani-Pace; Gursimran Kochhar; Brigid S Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Varun Kesar; Karen Lasch; Michelle Luo; Matthew Bohm; Sashidhar Varma; Monika Fischer; David Hudesman; Shannon Chang; Dana Lukin; Keith Sultan; Arun Swaminath; Nitin Gupta; Corey A Siegel; Bo Shen; William J Sandborn; Sunanda Kane; Edward V Loftus; Bruce E Sands; Jean-Frederic Colombel; Parambir S Dulai; Ryan Ungaro
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-06       Impact factor: 11.382
View more
  1 in total

Review 1.  Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.

Authors:  Laurent Peyrin-Biroulet; William J Sandborn; Remo Panaccione; Eugeni Domènech; Lieven Pouillon; Britta Siegmund; Silvio Danese; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2021-12-09       Impact factor: 4.409
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.